EA201170030A1 - Il-6-опосредованная иммунотерапия - Google Patents

Il-6-опосредованная иммунотерапия

Info

Publication number
EA201170030A1
EA201170030A1 EA201170030A EA201170030A EA201170030A1 EA 201170030 A1 EA201170030 A1 EA 201170030A1 EA 201170030 A EA201170030 A EA 201170030A EA 201170030 A EA201170030 A EA 201170030A EA 201170030 A1 EA201170030 A1 EA 201170030A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mediated immunotherapy
immunotherapy
mediated
recognize
compositions
Prior art date
Application number
EA201170030A
Other languages
English (en)
Other versions
EA019512B1 (ru
Inventor
Линда Мишер
Алан Кейт Лофквист
Питер Роберт Баум
Питер Армстронг Томпсон
Original Assignee
Эмерджент Продакт Дивелопмент Сиэтл, Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмерджент Продакт Дивелопмент Сиэтл, Ллс filed Critical Эмерджент Продакт Дивелопмент Сиэтл, Ллс
Publication of EA201170030A1 publication Critical patent/EA201170030A1/ru
Publication of EA019512B1 publication Critical patent/EA019512B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Полипептид связывающего домена и содержащие его гибридные белки, распознающие комплекс IL-6/рецептор IL-6, а также композиции и способы их применения.
EA201170030A 2008-07-02 2009-07-02 Il-6-опосредованная иммунотерапия EA019512B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7785908P 2008-07-02 2008-07-02
PCT/US2009/049593 WO2010003101A2 (en) 2008-07-02 2009-07-02 Il6 immunotherapeutics

Publications (2)

Publication Number Publication Date
EA201170030A1 true EA201170030A1 (ru) 2011-08-30
EA019512B1 EA019512B1 (ru) 2014-04-30

Family

ID=41170031

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170030A EA019512B1 (ru) 2008-07-02 2009-07-02 Il-6-опосредованная иммунотерапия

Country Status (12)

Country Link
US (1) US8632774B2 (ru)
EP (1) EP2313109A2 (ru)
JP (1) JP2012531885A (ru)
KR (1) KR20110043643A (ru)
CN (1) CN102264390A (ru)
AU (1) AU2009266856A1 (ru)
BR (1) BRPI0913991A2 (ru)
CA (1) CA2729747A1 (ru)
EA (1) EA019512B1 (ru)
IL (1) IL210347A0 (ru)
MX (1) MX2011000071A (ru)
WO (1) WO2010003101A2 (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741446B2 (en) 2006-08-18 2010-06-22 Armagen Technologies, Inc. Fusion antibodies that cross the blood-brain barrier in both directions
EP2182980A4 (en) 2007-07-27 2012-04-18 Armagen Technologies Inc METHOD AND COMPOSITIONS FOR INCREASED ALPHA IDURONIDASE ACTIVITY IN THE CNS
EP2310410A2 (en) * 2008-07-02 2011-04-20 Emergent Product Development Seattle, LLC Tnf- antagonist multi-target binding proteins
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
SG172754A1 (en) * 2008-10-10 2011-08-29 Trubion Pharmaceuticals Inc Tcr complex immunotherapeutics
JP5873003B2 (ja) * 2009-03-18 2016-03-01 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法
PT2485761T (pt) 2009-10-09 2019-05-30 Armagen Inc Métodos e composições para aumentar a atividade da iduronato 2-sulfatase no snc
WO2013075027A2 (en) * 2011-11-17 2013-05-23 Emergent Product Development Seattle, Llc Anti-sil6xr complex binding domains and methods of use
US8486399B2 (en) 2011-12-02 2013-07-16 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
KR20150004856A (ko) 2012-04-20 2015-01-13 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Cd3 결합 폴리펩타이드
MX2019001355A (es) 2012-05-10 2023-01-17 Bioatla Llc Anticuerpos monoclonales multiespecíficos.
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
MY181648A (en) 2012-08-24 2020-12-30 Univ California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
EP3062818B1 (en) 2013-11-01 2019-09-11 IBC Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
CN105198982B (zh) * 2014-06-18 2019-07-26 上海交通大学 基于il-6的抗原表位及其应用
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3242893A1 (en) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh) * 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
WO2016205042A1 (en) * 2015-06-16 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University SIRPα AGONIST ANTIBODY
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
CN110055224B (zh) * 2019-04-03 2023-06-30 深圳市体内生物医药科技有限公司 一种基因修饰的免疫细胞及其制备方法和应用
WO2020257586A2 (en) 2019-06-20 2020-12-24 Baxalta Incorporated Method of treatment with viral-based gene therapy
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US6672257B1 (en) * 1994-05-06 2004-01-06 Foster-Miller, Inc. Upper bundle steam generator cleaning system and method
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
US5919763A (en) * 1998-06-01 1999-07-06 Hadasit Medical Research Services And Development Company Ltd. IL-6/SIL-6R complex for promotion of liver functions
US20040170604A1 (en) * 1998-07-06 2004-09-02 Tosoh Corporation IL-6 receptor IL-6 direct fusion protein
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
GB0119015D0 (en) * 2001-08-03 2001-09-26 Univ Cardiff A fusion protein
WO2004039826A1 (en) * 2001-11-14 2004-05-13 Centocor, Inc. Anti-il-6 antibodies, compositions, methods and uses
DE10321317A1 (de) 2003-05-13 2004-12-23 Christian-Albrechts-Universität Zu Kiel Verfahren zum Nachweis des funktionellen IL-6/ sIL-6-Rezeptor-Komplexes und Test-Kit zur Durchführung dieses Verfahrens
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
AR057941A1 (es) * 2005-11-25 2007-12-26 Univ Keio Agentes terapeuticos para el cancer de prostata
PT1966244E (pt) * 2005-12-30 2012-05-17 Merck Patent Gmbh Anticorpos anti-il-6 impedindo a ligação da il-6 complexada com il-6ralfa a gp130
CA2654317A1 (en) * 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
US8153128B2 (en) * 2006-11-30 2012-04-10 Medimmune Limited Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor
AU2007331596A1 (en) 2006-12-13 2008-06-19 Ablynx N.V. Polypeptides specific for complexes involved in receptor-mediated signaling, such as the IL-6/IL-6 receptor complex
WO2009109584A1 (en) * 2008-03-07 2009-09-11 Ferring International Center S. A. ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
EP2310410A2 (en) * 2008-07-02 2011-04-20 Emergent Product Development Seattle, LLC Tnf- antagonist multi-target binding proteins
WO2010014629A1 (en) * 2008-07-28 2010-02-04 Trubion Pharmaceuticals, Inc. Multi-specific binding proteins targeting b cell disorders
EP3281955A1 (en) * 2008-10-02 2018-02-14 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
SG172754A1 (en) * 2008-10-10 2011-08-29 Trubion Pharmaceuticals Inc Tcr complex immunotherapeutics
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
EP3112382A1 (en) 2009-12-29 2017-01-04 Emergent Product Development Seattle, LLC Heterodimer binding proteins and uses thereof

Also Published As

Publication number Publication date
WO2010003101A3 (en) 2010-04-01
EA019512B1 (ru) 2014-04-30
KR20110043643A (ko) 2011-04-27
US8632774B2 (en) 2014-01-21
CN102264390A (zh) 2011-11-30
MX2011000071A (es) 2011-05-03
WO2010003101A2 (en) 2010-01-07
US20110142851A1 (en) 2011-06-16
CA2729747A1 (en) 2010-01-07
EP2313109A2 (en) 2011-04-27
BRPI0913991A2 (pt) 2015-11-17
IL210347A0 (en) 2011-03-31
AU2009266856A1 (en) 2010-01-07
JP2012531885A (ja) 2012-12-13

Similar Documents

Publication Publication Date Title
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
EA201890866A1 (ru) Связывающие молекулы, которые ингибируют рост рака
CR20120371A (es) Antagonistas de pcsk9
EA201891066A1 (ru) Антитела к ror1
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
EA201201435A1 (ru) ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
EA201790757A1 (ru) Связывающие антиген cd27l белки
MX2015005675A (es) Composiciones y metodos para modular la comunicacion celular.
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
EA201591467A1 (ru) Анти-lag-3 связывающие белки
EA200802168A1 (ru) Гуманизированное антитело к с-kit
UA112416C2 (uk) Антитіло до fap і способи його застосування
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA201001223A1 (ru) Стабилизированные белковые композиции
PE20140232A1 (es) Proteinas de enlace antigeno capaz de enlazar linfopoyetina estromal timica
MX343659B (es) Proteínas de unión receptoras fc.
EA201390923A1 (ru) Модифицированное антитело с улучшенным полупериодом существования
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы
EA201171494A1 (ru) Миметики белка smac
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU